Dupilumab improves quality of life in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial

<bold>BACKGROUND:</bold> Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, lowered exacerbation frequency and improved health-related quality of life and respiratory symptoms in phase 3 BOREAS (<ext-link>NCT03930732</ext-link>). Herein, we evaluated whether dupilumab results in an improvement in quality of life using the St. George’s Respiratory Questionnaire (SGRQ) in patients who did not experience an exacerbation (“non-exacerbators”) during BOREAS. <bold>METHODS:</bold> In BOREAS, patients with COPD with moderate-to-severe airflow limitation and type 2 inflammation (screening blood eosinophils ≥300 cells/µL), on triple therapy, received add-on dupilumab 300 mg q2w or placebo for 52 weeks. SGRQ total score was analyzed in the ITT and in non-exacerbators. <bold>RESULTS:</bold> In the ITT population, dupilumab (n=468) improved SGRQ score at Week 52 (least squares [LS] mean difference −3.363; <italic>P</italic>=0.0017) vs placebo (n=471). In non-exacerbators, mean baseline scores were similar for both treatment groups and, by Week 52, dupilumab (n=286) improved SGRQ scores (LS mean difference of −4.064; nominal <italic>P</italic>=0.0039) vs placebo (n=259) (Table). Dupilumab demonstrated an acceptable safety profile in the ITT population. <bold>CONCLUSIONS:</bold> Dupilumab led to an improvement in quality of life vs placebo in the ITT population and in the subgroup of non-exacerbators in BOREAS. <fig><object-id>erj;64/suppl_68/PA4784/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>